Singapore Looks Beyond its Shores
This article was originally published in SRA
John Lim, head of Singapore's health products regulatory agency, the HSA, tells Ian Haydock that alliances with international partners are critical to fulfilling the agency’s mission.
You may also be interested in...
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.